Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AKR1B1 | P15121 | 1/20 | 0.65 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.62 |
| ▸ | PPARG | P37231 | 7/20 | 0.62 |
| ▸ | PPARD | Q03181 | 7/20 | 0.62 |
| ▸ | PPARA | Q07869 | 7/20 | 0.62 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.62 |
| ▸ | TSHR | P16473 | 4/20 | 0.62 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | TLR2 | O60603 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.62 |
| ▸ | FABP4 | P15090 | 2/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.62 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.62 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.62 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | ESR1 | P03372 | 1/20 | 0.62 |
| ▸ | PDE4A | P27815 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26034547 | 0.98 | AKR1B1 (0.62) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL7198136 | 0.98 | GPR84 (0.67) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL8088473 | 0.98 | GPR84 (0.67) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL3216776 | 0.98 | GPR84 (0.67) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL21062665 | 0.98 | GPR84 (0.67) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL6426089 | 0.98 | GPR84 (0.67) | AKR1B1GPR84PPARGPPARDPPARA | |
| Adipic Acid SCHEMBL2512259 | 0.98 | AKR1B1 (0.68) | AKR1B1GPR84PPARGPPARDPPARA | |
| SCHEMBL9007925 | 0.96 | GPR84 (0.64) | AKR1B1GPR84PPARGPPARDPPARA | |
| Adipic Acid SCHEMBL52475 | 0.95 | AKR1B1 (0.65) | AKR1B1GPR84PPARGPPARDPPARA | |
| Adipic Acid SCHEMBL28409819 | 0.95 | AKR1B1 (0.65) | AKR1B1GPR84PPARGPPARDPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11827636-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-22 | — | — | US | disclosed |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-08-01 | — | — | US | disclosed |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-27 | — | — | US | disclosed |
| US-10391750-B2 | Cover window plate and image display device including the same | DONGWOO FINE-CHEM CO., LTD. (KR) | 2019-08-27 | — | — | US | disclosed |
| US-20180178494-A1 | COVER WINDOW PLATE AND IMAGE DISPLAY DEVICE INCLUDING THE SAME | DONGWOO FINE-CHEM CO., LTD. (KR) | 2018-06-28 | — | — | US | disclosed |
| US-9809588-B2 | GLS1 inhibitors for treating disease | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-11-07 | — | — | US | disclosed |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2017-10-12 | — | — | US | disclosed |
| US-9480754-B2 | Phospholipid ether analogs as cancer-targeting drug vehicles | CELLECTAR BIOSCIENCES, INC. (US) | 2016-11-01 | — | — | US | disclosed |
| US-20120270142-A1 | PHOTOSENSITIVE COMPOSITION AND METHOD OF MANUFACTURING A SUBSTRATE FOR A DISPLAY DEVICE USING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-10-25 | — | — | US | disclosed |
| US-20120064455-A1 | PHOTORESIST COMPOSITION AND METHOD OF FORMING PATTERN USING THE SAME | SAMSUNG TECHWIN CO., LTD. (KR) | 2012-03-15 | — | — | US | disclosed |
| US-7893268-B2 | Epithiolone analogues | UNIVERSITY OF TOLEDO (US) | 2011-02-22 | — | — | US | disclosed |
| US-20090258904-A1 | Epithiolone Analogues | UNIVERSITY OF TOLEDO | 2009-10-15 | — | — | US | disclosed |
| US-20060177767-A1 | Photosensitive resin composition, thin film panel including a layer made from photosensitive resin composition, and method for manufacturing thin film panel | SAMSUNG ELECTRONICS CO., LTD. | 2006-08-10 | — | — | US | disclosed |
| US-20050042536-A1 | Photosensitive resin composition comprising quinonediazide sulfate ester compound | DONGJIN SEMICHEM CO. LTD. (KR) | 2005-02-24 | — | — | US | disclosed |
| WO-2003036388-A1 | PHOTOSNESITIVE RESIN COMPOSITION COMPRISING QUINONEDIAZIDE SULFATE ESTER COMPOUND | DONGJIN SEMICHEM CO., LTD. (KR) | 2003-05-01 | — | — | WO | disclosed |
| EP-0268820-B1 | PROCESS FOR PRODUCING 2-ACYLFURAN DERIVATIVES | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1990-09-19 | — | — | EP | disclosed |
| US-4812585-A | REACTING A FURAN COMPOUND WITH A MIXED ACID ANHYDRIDE IN THE PRESENCE OF A BORON TRIFLUORIDE COMPLEX CATALYST | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1989-03-14 | — | — | US | disclosed |
| EP-0268820-A2 | Process for producing 2-acylfuran derivatives | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 1988-06-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11827636-B2 | Degradation of cyclin-dependent kinase 8 (CDK8) by conjugation of CDK8 inhibitors with E3 ligase ligand and methods of use | CDK8, CDK18, CDKL3 | AKR1B1 1050/4885GPR84 3189/4885PPARG 2792/4885 |
| US-11712458-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | AKR1B1 2562/4885GPR84 2968/4885PPARG 4711/4885 |
| US-20090258904-A1 | Epithiolone Analogues | ESRRB, ESR2, ESRRA | AKR1B1 1540/4885GPR84 1576/4885PPARG 518/4885 |
| US-20230131952-A1 | DEGRADATION OF PROTEIN KINASES BY CONJUGATION OF PROTEIN KINASE INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | MDM2, MAP2K2, TTK | AKR1B1 1059/4885GPR84 3107/4885PPARG 4045/4885 |
| US-11730818-B2 | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use | BTK, CBL, SYK | AKR1B1 2373/4885GPR84 3049/4885PPARG 4728/4885 |
| US-20230338551-A1 | DEGRADATION OF BRUTON'S TYROSINE KINASE (BTK) BY CONJUGATION OF BTK INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE | BTK, CBL, SYK | AKR1B1 2373/4885GPR84 3049/4885PPARG 4728/4885 |
| US-20170291895-A1 | GLS1 INHIBITORS FOR TREATING DISEASE | GLS2, GLS, GLG1 | AKR1B1 760/4885GPR84 843/4885PPARG 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.